APTO - Aptose shares continue drop in fallout from AML data but Street firms remain bullish

Shares of Aptose Biosciences (APTO -42.6%) are tumbling today after releasing data yesterday at a major medical conference on its acute myeloid leukemia candidate HM43239. RBC Capital Markets, however, is maintaining its outperform rating with a $9 price target (~362% upside based on yesterday's close). Analyst Gregory Renza said it is worth continuing to pay attention to the candidate as the company expands enrollment into additional cohorts. Alliance Global Partners is still bullish on Aptose, but cut its price target to $8 from $12 as a result (310% upside) on yesterday's data. #ASH2021 Read about the Aptose's license agreement with Hanmi Pharmaceutical for HM43239.

For further details see:

Aptose shares continue drop in fallout from AML data, but Street firms remain bullish